Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Protease-targeted chimeras (PROTACs) are a new technology that is receiving much
attention in the treatment of diseases. The mechanism is to inhibit protein function by …

Background Peptide proteolysis-targeting chimeras (p-PROTACs) with advantages of high
specificity and low toxicity have emerged as a powerful technology of targeted protein …

Despite recent advances in molecular therapeutics, lung cancer is still a leading cause of
cancer deaths. Currently, limited targeted therapy options and acquired drug resistance …

Heterobifunctional degraders, known as proteolysis targeting chimeras (PROTACs),
theoretically possess a catalytic mode-of-action, yet few studies have either confirmed or …

Huntington's disease (HD) is a neurodegenerative disorder caused by the aggregation of
the mutant huntingtin (mHTT) protein in nerve cells. mHTT self-aggregates to form soluble …

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and
synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two …